Janssen Booster Evidence Draws Questions From US FDA, But Also A Nod Towards Benefits

 
• By Derrick Gingery

Agency assessors couldn’t independently verify several Janssen analyses of booster shot data and raised concerns about small samples sizes and an unvalidated immunogenicity assay.

US COVID-19 vaccination card with Janssen
The FDA's Vaccines and Related Biological Products Advisory Committee will consider whether a Janssen COVID-19 vaccine booster should be recommended. • Source: Alamy

More from Vaccines

More from Pink Sheet